Skip to main content

Table 2 Patients' baseline demographics and biochemical data

From: Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)

 

Atorvastatin

n= 49

Placebo

n= 51

P-value

Age, years, mean (SD)

62.8 (21.2)

64 (15.6)

0.745

Male gender, %

51

51

0.570

Scoring systems

   

MEWS, mean (SD)

2.8 (2.1)

3.3 (2.1)

0.197

APACHE II, mean (SD)

11.8 (5.6)

11.9 (6.0)

0.914

Predicted mortality, median (IQR)

14.6 (8.7, 23.5)

12.9 (7.6, 26.2)

0.909

Biochemical data

Cholesterol, mmol/L, median (IQR)

4.0 (2.9, 5.1)

4.35 (3.35, 5.35)

0.505

Neutrophils, × 109/L median (IQR)

11.6 (8.3, 13.7)

12.4 (9.3, 19.4)

0.232

C-reactive protein, mg/L, mean (SD)

194.6 (114.6)

188.0 (127.3)

0.683

Source of infection, number of cases

Pneumonia

27

24

0.674

Urinary tract

8

9

0.808

Cellulitis

6

10

0.317

Gastrointestinal

5

7

0.563

Bacteraemia

2

1

0.563

Urinary catheter

1

0

0.317

Antibiotic therapy, number of patients

38

42

0.654

Co-morbidities, number of patients

0

15

17

0.832

1

22

21

0.840

2

7

6

0.772

3 or more

5

8

0.554

Number of trial drug doses, median (IQR)

3 (2, 7)

5 (2, 8)

0.322

  1. MEWS, modified early warning score; APACHE, acute physiology and chronic health evaluation; IQR, interquartile range.